Medicine & Life Sciences
Non-Small Cell Lung Carcinoma
100%
Clinical Trials
90%
Neoplasms
65%
Survival
54%
Lung Neoplasms
52%
Progression-Free Survival
43%
Biomarkers
40%
Therapeutics
39%
Small Cell Lung Carcinoma
29%
PCI 32765
27%
Response Evaluation Criteria in Solid Tumors
26%
Drug Therapy
25%
B-Cell Chronic Lymphocytic Leukemia
23%
Bortezomib
22%
Acute Myeloid Leukemia
21%
Placebos
21%
Sulindac
21%
Multiple Myeloma
20%
Carboplatin
19%
Genotype
19%
midostaurin
19%
Pemetrexed
18%
Chemoprevention
18%
National Cancer Institute (U.S.)
18%
Maximum Tolerated Dose
18%
Confidence Intervals
18%
Sorafenib
17%
pomalidomide
17%
Bendamustine Hydrochloride
16%
Meta-Analysis
16%
Radiotherapy
15%
Data Analysis
15%
Safety
15%
Guidelines
15%
Rituximab
15%
Lenalidomide
14%
Quality of Life
14%
Random Allocation
14%
Consent Forms
14%
Precision Medicine
14%
Brachytherapy
14%
Patient Selection
13%
Platinum
13%
Sample Size
13%
Drug Development
12%
Population
11%
Elderly
11%
Paclitaxel
11%
Appointments and Schedules
11%
tanespimycin
11%
Mathematics
Toxicity
30%
Dose
25%
Design
23%
Dose Finding
22%
Oncology
18%
Cancer
14%
Efficacy
13%
Drugs
13%
Clinical Trials
11%
Regulator
7%
Assignment
6%
Phase I Trial
6%
Continual Reassessment Method
6%
Modular Design
5%
Biomarkers
5%
Therapy
5%
Treatment Effects
5%